Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

GW Pharma Relocates CEO and Taps Ex-Allergan Exec to Lead U.S. Biz in SoCal

GW Appoints Senior Industry Executive to President, North America and Relocates CEO to the U.S. U.S. Operations to be Located in Southern California LONDON, May 19, 2015 (GLOBE NEWSWIRE via COMTEX) — GW Pharmaceuticals plc (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary […]

Read More »

Boehringer Ingelheim acquires Pharmaxis’ phase 1 anti-inflammatory drug candidate

FRENCHS FOREST, Australia & INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences. PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor discovered […]

Read More »

Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader

DUBLIN and WOODCLIFF LAKE, N.J., May 18, 2015 /PRNewswire/ — • Transaction valued at $8.05 billion is transformative for Endo, creating a powerful platform for future growth and further strategic M&A• Creates specialty pharmaceutical company with one of industry’s fastest growing generics businesses and expanded product portfolio, pipeline, technology platform and manufacturing capabilities• Positions Endo […]

Read More »

Johnson & Johnson Commits $25 Million to Operation Smile Over Next Five Years

NEW YORK, May 18, 2015 /PRNewswire/ — Hundreds gathered Thursday night at Cipriani 42nd Street in New York to recognize those who have supported Operation Smile, the world’s largest medical charity of its kind providing free cleft surgery and care. Johnson & Johnson committed $25 million in financial and product contributions to Operation Smile over the […]

Read More »

BioPharma M&A: Capital Efficiency Drives Returns

Amidst lofty public markets and robust fund flows, it’s easy to forget the importance of equity capital efficiency in building new biotech companies. But like gravity, it’s a fundamental principle and rests at the heart of generating quality returns in any market. By deploying early, expensive equity dollars carefully and thoughtfully, a startup can preserve […]

Read More »

Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company?

The success of a CEO is often predicated on the situational status of the company he or she inherits. Bill Steere took the helm at Pfizer in 1991, riding on the crest of five recently launched blockbusters: Zoloft, Norvasc, Zithromax, Diflucan, and Cardura. He then oversaw the rollout of Viagra and, if all this wasn’t […]

Read More »

U.S. class action asserts India’s Ranbaxy manipulated FDA rules

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Reuters/Ajay Verma Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market. […]

Read More »

Ogilvy CommonHealth Worldwide’s Jill Lesiak Honored as HBA Rising Star

PARSIPPANY, NJ–(Marketwired – May 14, 2015) – Ogilvy CommonHealth Worldwide (, the health behavior change experts of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced Jill Lesiak, vice president, creative director at the network’s Parsippany-based agency, Ogilvy CommonHealth, was named an industry Rising Star by the Healthcare Businesswomen’s Association (HBA) […]

Read More »

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

OSAKA, Japan, May 15, 2015 /PRNewswire/ — Operational guidance met  Growth supported by innovative new products  Regional top line performance on track  Efficiency gains above target  Exceptional items impacting bottom line  Guidance: Back to profitable growth from FY2015  180 yen dividend per share for FY2015 and strives to at least maintain the 180 yen annual dividend per […]

Read More »

Investing in Cannabis Testing Labs and Expansion of Marijuana News Focus of DigiPath, Inc., 10-Q

LAS VEGAS, May 13, 2015 /PRNewswire/ — DigiPath, Inc. (OTCBB and OTCQB: DIGP), the independent cannabis testing, media, digital pathology, and education firm, announced the filing of its quarterly report on Form 10-Q for its second fiscal quarter ended March 31, 2015, with the Securities and Exchange Commission. “DigiPath ended the quarter with $3.9 million of […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom